Caricamento...
A Cost-Utility Analysis of Switching from Reference to Biosimilar Infliximab Compared to Maintaining Reference Infliximab in Adult Patients with Crohn’s Disease
BACKGROUND AND AIMS: Lower-cost biosimilar infliximab may address affordability concerns in the treatment of adults with Crohn’s disease (CD), however, evidence regarding the cost-effectiveness of switching from reference to biosimilar is warranted. The aim of this research was to assess the increme...
Salvato in:
| Pubblicato in: | J Can Assoc Gastroenterol |
|---|---|
| Autori principali: | , , , |
| Natura: | Artigo |
| Lingua: | Inglês |
| Pubblicazione: |
Oxford University Press
2020
|
| Soggetti: | |
| Accesso online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7898373/ https://ncbi.nlm.nih.gov/pubmed/33644677 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/jcag/gwz045 |
| Tags: |
Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !
|